Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study

摘要: Objectives Some targeted therapies have improved survival and overall quality of cancer care generally, but these increasingly expensive medicines led to increases in pharmaceutical expenditure. This study examined trends use expenditures antineoplastic agents Taiwan, estimated market shares by prescription volume costs over time. We also determined which types accounted for the highest therapies. Design is a retrospective observational focusing on utilisation treatment cancer. Setting The monthly claims data were retrieved from Taiwan9s National Health Insurance Research Database (2009–2012). Main outcome measures calculated each class agent type. Using time series design with Autoregressive Integrated Moving Average (ARIMA) models, we Results Among all agents, grew 6.24% 2009 12.29% 2012, their rose 26.16% 41.57% that Monoclonal antibodies protein kinase inhibitors contributed most (respectively, 23.84% 16.12% 2012). During 2009–2012, lung (44.64% use; 28.26% costs), female breast (16.49% 27.18% costs) colorectal (12.11% 13.16% cancers Conclusions In are used different cancers, representing substantial economic burden. It important establish mechanisms monitor outcomes.